Tarsus Pharmaceuticals (TARS) Non Operating Income (2019 - 2026)

Tarsus Pharmaceuticals' Non Operating Income history runs 8 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 1960.49% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $5.0 million (up 201.82% YoY), while the FY2025 annual figure was $6.6 million, up 3308.74% from the prior year.
• Non Operating Income was $1.5 million for Q1 2026 at Tarsus Pharmaceuticals, down from $1.7 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $2.0 million in Q1 2024 to a low of -$4.4 million in Q4 2023.
• Historically, Non Operating Income has averaged $521235.3 across 5 years, with a median of $390000.0 in 2022.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income jumped 7700.0% in 2022, then sank 1308.33% in 2025.
• A 5-year view of Non Operating Income shows it stood at $931000.0 in 2022, then slumped by 577.23% to -$4.4 million in 2023, then jumped by 99.39% to -$27000.0 in 2024, then jumped by 6255.56% to $1.7 million in 2025, then decreased by 9.33% to $1.5 million in 2026.
• The last three Non Operating Income figures came in at $1.5 million (Q1 2026), $1.7 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.